PT-141

**PT-141 (Bremelanotide Acetate)** **For In-Vitro Research and Laboratory Use Only** PT-141, a synthetic peptide analog of the naturally occurring α-Melanocyte-stimulating hormone (α-MSH), is a potent non-selective agonist of the melanocortin receptors. Derived from the cyclic peptide Melanotan II, PT-141 differs significantly by the replacement of the C-terminal carboxylic acid with a primary alcohol. This structural modification shifts its pharmacological profile, maintaining high affinity for the MC3R and MC4R subtypes while exhibiting reduced activity at the MC1R (pigmentation) receptor compared to its predecessor. In laboratory settings, PT-141 is primarily investigated for its unique mechanism of action within the central nervous system (CNS). Unlike pro-erectile compounds that target the vascular system via the pde5 pathway, PT-141 exerts its effects upstream by modulating neuronal signaling in the hypothalamus, particularly within the medial preoptic area (mPOA). Research applications for PT-141 focus heavily on its ability to cross the blood-brain barrier and stimulate neural pathways associated with appetitive behaviors and sexual motivation in animal models. Preclinical studies have utilized this peptide to explore the complex interplay between melanocortin signaling and the dopaminergic reward system. By activating MC4 receptors, PT-141 has been shown to trigger oxytocin release and enhance dopamine neurotransmission, providing a valuable tool for behavioral neuroscientists studying the neurobiological underpinnings of social bonding, arousal, and autonomic function. Furthermore, the peptide is frequently employed in studies regarding hemorrhagic shock and inflammatory modulation, as melanocortin agonists have demonstrated potential in mitigating systemic inflammatory responses in specialized in-vitro assays. For optimal experimental integrity, PT-141 is supplied as a lyophilized white powder and should be stored at -20°C for long-term stability. Upon reconstitution with Bacteriostatic Water or Sterile Saline, the solution should be kept at 2-8°C and utilized within a narrow window—typically 7 to 14 days—to prevent peptide degradation and maintain biochemical potency. Researchers should avoid repeated freeze-thaw cycles of the reconstituted peptide. Laboratory handling should be conducted under aseptic conditions, and researchers must ensure that all protocols are strictly limited to in-vitro or animal-based models, as PT-141 is not approved for human consumption or clinical application in a research context.